MAGNESIUM OROTATE IN COMPLEX THERAPY OF METABOLIC DISORDERS IN PATIENTS WITH GOUT

Authors

  • S. I. Smiian SHEE Ternopil State Medical University Shrew Ternopil University Hospital
  • M. V. Franchuk SHEE Ternopil State Medical University Shrew Ternopil University Hospital
  • L. V. Balaban Shrew Ternopil University Hospital

DOI:

https://doi.org/10.11603/2415-8798.2017.1.7353

Keywords:

gout, metabolic syndrome, magnesium orotate.

Abstract

In 25–90 % patients with gout we detect metabolic syndrome (MS), and on the contrary – in patients with MS significantly increases the risk of gout and hyperuricemia (HU). About 40–50 % of MS cases are combined with magnesium deficiency. Comprehensive treatment of MS with the addition of magnesium drugs leads to more effective normalization of lipid and glycemic profiles, lowering blood pressure, prevention of atherosclerosis.

The aim of the study – determining the prevalence of MS and diabetes mellitus in patients with gout and the possibility of its correction.

Materials and Methods. We examined 45 patients with gout in Rheumatology Department of Ternopil University hospital. Patients were divided into two groups: I group (n=23) – received standard hypouricemic treatment by Allopurinol, NSAIDs, and magnesium orotate in a daily dose of 1500 mg. Patients of group II (n=22), control group, received only Allopurinol and NSAIDs.

Results and Discussion. Dynamic monitoring of the main clinical and laboratory parameters indicated that patients who received the combined therapy with magnesium orotate showed significantly better outcomes than the control group.

Conclusion. Magnesium orotate can be recommended in gout treatment for metabolic disorders.

Author Biography

S. I. Smiian, SHEE Ternopil State Medical University Shrew Ternopil University Hospital

заведующий кафедрой внутренней медицины № 2

References

Shilov, А.M., Avshalumov, А.Sh., & Markovskiy V.B. (2009). Vzaimosviaz defitsita vagniya I metabolicheskogo sindroma [Relationship of magnesium deficiency and the metabolic syndrome]. Ruskiy meditsinskiy zhurnal – Russian Medical Journal, 17, 3 [in Russian].

Kravchun, P.G., Krapyvko, S.А., & Kravchun, P.P. (2012). Vliyaniye magniya orotata na lipidnyi obmen u bolnykh khronicheskoy serdechnoy nedostatochnistyu s suputstvuyushchim sakharnym diabetom 2 tipa [Effect of magnesium orotate on lipid metabolism in patients with chronic heart failure with concomitant diabetes type 2]. Mezhdunarodnyi endokrinologicheskiy zhurnal – International Endocrinological Journal, 2 (42), 12 [in Russian].

Teodorovych, О.V. (2008). Narusheniye obmena mochevoy kisloty u bolnykh sakharnym diabetom 2 tipa [Violation of uric acid metabolism in patients with type 2 diabetes]. RMZh – RMJ, 15, 985-988 [in Russian].

Shuba, N.М. (2013). Giperurikemiya – multimorbidnaya patologiya v revmatologiii [Hyperuricemia – multimorbid pathology in rheumatology]. Ukrainskyi revmatolohichnyi zhurnal – Ukrainian Rheumatologic Journal, 52 [in Russian].

Kao, M.P.C. (2010). Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic option. Journal of Human Hypertension, 24, 1-8.

Muirden, K.D. (2010). Community Oriented Program for the Control of Rheumatic Diseases. Studies of rheumatic diseases in the developing world II, 17, 153-156.

Nakagawa, T. (2003). Hyperuricemia causes glomerular hypertrophy in the rat. Am. J. Nephrol. 23, 2-7.

Roddy, Е. (2010). Effect of insulin on renal sodium and uric acid handling in essentia hypertension. Am. J. Hypertens.

Singh, J.A. (2008). Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans II. Ann. Rheum. Dis., 67, 1310-1316.

Stoller, M.L., & Meng, M.V. (2007). Urinary stone disease. New Jersey: Humana Presse Inc.

Woodward, О.M. (2009). Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. PNAS, 3, 10338-10342.

Downloads

Published

2017-04-27

How to Cite

Smiian, S. I., Franchuk, M. V., & Balaban, L. V. (2017). MAGNESIUM OROTATE IN COMPLEX THERAPY OF METABOLIC DISORDERS IN PATIENTS WITH GOUT. Bulletin of Scientific Research, (1). https://doi.org/10.11603/2415-8798.2017.1.7353

Issue

No. 1 (2017)

Section

INTERNAL MEDICINE

License

Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. Результат пошуку зображень за запитом "CC-BY logo"         

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)